Jacobs Levy Equity Management
ESPR

Jacobs Levy Equity Management’s Esperion Therapeutics ESPR Stock Holding History

Jacobs Levy Equity Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-595,016
Closed -$1.32M – 980
2024
Q2 		$1.32M Sell
595,016
-109,081
-15% -$257K 0.01% 676
2024
Q1 		$1.89M Sell
704,097
-353,787
-33% -$860K 0.01% 606
2023
Q4 		$3.16M Sell
1,057,884
-1,206,475
-53% -$1.56M 0.02% 514
2023
Q3 		$2.22M Buy
2,264,359
+1,836,567
+429% +$2.66M 0.01% 544
2023
Q2 		$595K Buy
427,792
+272,289
+175% +$380K ﹤0.01% 789
2023
Q1 		$247K Buy
155,503
+9,484
+6% +$49K ﹤0.01% 885
2022
Q4 		$910K Buy
+146,019
New +$1.04M 0.01% 691
2021
Q1 		– Sell
-35,072
Closed -$912K – 1048
2020
Q4 		$912K Buy
35,072
+120
+0.3% +$3.6K 0.01% 746
2020
Q3 		$1.3M Sell
34,952
-3,668
-9% -$145K 0.01% 606
2020
Q2 		$1.98M Buy
38,620
+461
+1% +$19.3K 0.02% 534
2020
Q1 		$1.2M Sell
38,159
-3,088
-7% -$163K 0.02% 583
2019
Q4 		$2.46M Buy
41,247
+8,937
+28% +$402K 0.02% 510
2019
Q3 		$1.18M Buy
32,310
+1,260
+4% +$49.9K 0.01% 592
2019
Q2 		$1.44M Sell
31,050
-670
-2% -$31.5K 0.02% 577
2019
Q1 		$1.27M Buy
31,720
+23,570
+289% +$1.06M 0.02% 613
2018
Q4 		$375K Buy
8,150
+300
+4% +$14.5K 0.01% 778
2018
Q3 		$348K Buy
+7,850
New +$360K ﹤0.01% 847
2016
Q2 		– Sell
-18,500
Closed -$313K – 1172
2016
Q1 		$313K Buy
+18,500
New +$298K 0.01% 860

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jacobs Levy Equity Management's ESPR Position: Q3 2024 in Review

Jacobs Levy Equity Management sold out of Esperion Therapeutics (ESPR) in Q3 2024, closing a stake of 595,016 shares — an estimated $1.32M sold.

Jacobs Levy Equity Management first reported a position in ESPR in Q1 2016 and held it in 18 quarters. The position peaked at $3.16M in Q4 2023. 183 funds tracked by Wall St. Rank hold ESPR as of Q3 2024.

  • Jacobs Levy Equity Management reported no remaining Esperion Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 595,016 Esperion Therapeutics shares in Q3 2024, an estimated $1.32M.
  • Jacobs Levy Equity Management first reported a position in Esperion Therapeutics in Q1 2016 and held it in 18 quarters.
  • Jacobs Levy Equity Management's Esperion Therapeutics position peaked at $3.16M in Q4 2023.
  • 183 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2024, filed 14 Nov 2024.